English, Article edition: Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia Alexander H. Miners; Caroline A. Sabin; Keith H. Tolley; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118469
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia
Author
  • Alexander H. Miners
  • Caroline A. Sabin
  • Keith H. Tolley
  • Christine A. Lee
Physical Description
  • article
Notes
  • Objective: To assess the cost effectiveness of primary prophylaxis with clotting factor instead of treatment following a bleed (on-demand) for individuals with severe haemophilia. Design: Different data sources on the clinical effects and costs of treatments were combined using a Markov model. Setting: English treatment centres. Perspective: UK societal. Participants: Hypothetical cohorts of 100 individuals with severe haemophilia A or B or severe von Willebrands disease. Interventions: Primary prophylaxis treatment on-demand with clotting factor. Outcome measures: Costs, quality-adjusted life-years (QALYs) and incremental cost per QALY in UK pounds (Lstg , 1999/​2000 values). Results: The baseline results showed that treating individuals with severe haemophilia A/​severe von Willebrands disease or severe haemophilia B with primary prophylaxis instead of treatment on-demand cost an additional Lstg 46 500 and Lstg 8600 per QALY gained, respectively. However, the results were extremely sensitive to a number of factors including the clotting factor unit cost, the time between prophylactic doses and the discount rate. Conclusions: Despite the high costs of treatment, primary prophylaxis was cost effective compared with treatment on-demand in some scenarios. Primary prophylaxis is more likely to be cost effective for individuals with severe haemophilia B compared with individuals with severe haemophilia A/​severe von Willebrands disease. Further research is required to assess the relationship between methods of clotting factor infusion and health-related quality-of-life.
  • Antihaemorrhagics, Cost utility, Haemophilia, Pharmacoeconomics
  • RePEc:wkh:phecon:v:20:y:2002:i:11:p:759-774
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment